The top priorities are:
• $20 million in bonding to build a bioscience research facility build a 45,000 sf research facility at the Mayo Clinic in Rochester to be jointly developed by the University of Minnesota and the Mayo Clinic;
• $15 million in bonding for development grants to be competed for by the state's three bioscience zones in Minneapolis, St. Paul and Rochester.
Other proposed measures include doubling to $2 million the maximum value of tax exemptions offered in the bioscience zones. Additionally, $100,000 would be provided in order to operate an office that helps small companies secure federal research funding.
Meanwhile, at least one of the key recommendations is already running into opposition. Rep. Phillip Krinkie, R-Shoreview, assistant majority leader and chairman of the capital investment committee, says he plans to nix the $20 million requested to build the research facility at the Mayo Clinic. Pawlenty says he hopes that a little education about the initiative "will change his mind."
In fact, biosciences supporters hoped to educate state legislators about the potential of Minnesota's biosciences in "Biosciences 101," a three-hour informational event to be held in St. Paul Wednesday afternoon. Bio 101 will discuss issues in the biosciences industry, how the initiative could create jobs for Minnesotans and how the government could help facilitate the industry's grow here.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
